Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California. more
Time Frame | VXRT | Sector | S&P500 |
---|---|---|---|
1-Week Return | -11.92% | -2.06% | -0.55% |
1-Month Return | -11.48% | -1.92% | 2.72% |
3-Month Return | -40.01% | -10.4% | 7.66% |
6-Month Return | -21.01% | -4.6% | 10.15% |
1-Year Return | -13.27% | 4.06% | 27.53% |
3-Year Return | -92.82% | 1.94% | 32.31% |
5-Year Return | 80% | 36.48% | 89.2% |
10-Year Return | -97.95% | 97.46% | 194.59% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 9.86M | 4.05M | 892.00K | 107.00K | 7.38M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":41.03,"profit":true},{"date":"2021-12-31","value":9.04,"profit":true},{"date":"2022-12-31","value":1.08,"profit":true},{"date":"2023-12-31","value":74.82,"profit":true}] |
Cost of Revenue | 14.54M | 19.86M | 48.75M | 3.27M | 68.14M | [{"date":"2019-12-31","value":21.34,"profit":true},{"date":"2020-12-31","value":29.15,"profit":true},{"date":"2021-12-31","value":71.54,"profit":true},{"date":"2022-12-31","value":4.79,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (4.68M) | (15.82M) | (47.86M) | (3.16M) | (60.76M) | [{"date":"2019-12-31","value":-467800000,"profit":false},{"date":"2020-12-31","value":-1581700000,"profit":false},{"date":"2021-12-31","value":-4785700000,"profit":false},{"date":"2022-12-31","value":-316000000,"profit":false},{"date":"2023-12-31","value":-6076300000,"profit":false}] |
Gross Margin | (47.43%) | (390.93%) | (5365.13%) | (2953.27%) | (823.46%) | [{"date":"2019-12-31","value":-47.43,"profit":false},{"date":"2020-12-31","value":-390.93,"profit":false},{"date":"2021-12-31","value":-5365.13,"profit":false},{"date":"2022-12-31","value":-2953.27,"profit":false},{"date":"2023-12-31","value":-823.46,"profit":false}] |
Operating Expenses | 20.73M | 35.06M | 70.64M | 110.44M | 90.73M | [{"date":"2019-12-31","value":18.77,"profit":true},{"date":"2020-12-31","value":31.75,"profit":true},{"date":"2021-12-31","value":63.96,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":82.15,"profit":true}] |
Operating Income | (15.79M) | (30.17M) | (72.75M) | (114.59M) | (83.35M) | [{"date":"2019-12-31","value":-1578500000,"profit":false},{"date":"2020-12-31","value":-3017000000,"profit":false},{"date":"2021-12-31","value":-7275200000,"profit":false},{"date":"2022-12-31","value":-11458700000,"profit":false},{"date":"2023-12-31","value":-8334700000,"profit":false}] |
Total Non-Operating Income/Expense | (7.29M) | (3.61M) | 990.00K | 6.84M | 2.35M | [{"date":"2019-12-31","value":-106.61,"profit":false},{"date":"2020-12-31","value":-52.81,"profit":false},{"date":"2021-12-31","value":14.48,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":34.34,"profit":true}] |
Pre-Tax Income | (18.16M) | (31.98M) | (70.36M) | (107.69M) | (82.20M) | [{"date":"2019-12-31","value":-1815500000,"profit":false},{"date":"2020-12-31","value":-3198200000,"profit":false},{"date":"2021-12-31","value":-7036300000,"profit":false},{"date":"2022-12-31","value":-10769100000,"profit":false},{"date":"2023-12-31","value":-8220400000,"profit":false}] |
Income Taxes | 490.00K | 238.00K | 107.00K | 67.00K | 261.00K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":48.57,"profit":true},{"date":"2021-12-31","value":21.84,"profit":true},{"date":"2022-12-31","value":13.67,"profit":true},{"date":"2023-12-31","value":53.27,"profit":true}] |
Income After Taxes | (18.64M) | (32.22M) | (70.47M) | (107.76M) | (82.47M) | [{"date":"2019-12-31","value":-1864500000,"profit":false},{"date":"2020-12-31","value":-3222000000,"profit":false},{"date":"2021-12-31","value":-7047000000,"profit":false},{"date":"2022-12-31","value":-10775800000,"profit":false},{"date":"2023-12-31","value":-8246500000,"profit":false}] |
Income From Continuous Operations | (18.64M) | (32.22M) | (70.47M) | (107.76M) | (82.47M) | [{"date":"2019-12-31","value":-1864500000,"profit":false},{"date":"2020-12-31","value":-3222000000,"profit":false},{"date":"2021-12-31","value":-7047000000,"profit":false},{"date":"2022-12-31","value":-10775800000,"profit":false},{"date":"2023-12-31","value":-8246500000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (18.64M) | (32.22M) | (70.47M) | (107.76M) | (82.47M) | [{"date":"2019-12-31","value":-1864500000,"profit":false},{"date":"2020-12-31","value":-3222000000,"profit":false},{"date":"2021-12-31","value":-7047000000,"profit":false},{"date":"2022-12-31","value":-10775800000,"profit":false},{"date":"2023-12-31","value":-8246500000,"profit":false}] |
EPS (Diluted) | (1.02) | (0.35) | (0.58) | (0.84) | (0.58) | [{"date":"2019-12-31","value":-102,"profit":false},{"date":"2020-12-31","value":-35,"profit":false},{"date":"2021-12-31","value":-58,"profit":false},{"date":"2022-12-31","value":-84,"profit":false},{"date":"2023-12-31","value":-58,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
VXRT | |
---|---|
Cash Ratio | 0.73 |
Current Ratio | 0.83 |
Quick Ratio | 0.88 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
VXRT | |
---|---|
ROA (LTM) | -39.68% |
ROE (LTM) | -91.66% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
VXRT | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.59 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.41 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
VXRT | |
---|---|
Trailing PE | NM |
Forward PE | 42.73 |
P/S (TTM) | 9.65 |
P/B | 1.96 |
Price/FCF | NM |
EV/R | 4.66 |
EV/Ebitda | NM |
Vaxart Inc (VXRT) share price today is $0.563
Yes, Indians can buy shares of Vaxart Inc (VXRT) on Vested. To buy Vaxart Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VXRT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Vaxart Inc (VXRT) via the Vested app. You can start investing in Vaxart Inc (VXRT) with a minimum investment of $1.
You can invest in shares of Vaxart Inc (VXRT) via Vested in three simple steps:
The 52-week high price of Vaxart Inc (VXRT) is $1.54. The 52-week low price of Vaxart Inc (VXRT) is $0.52.
The price-to-earnings (P/E) ratio of Vaxart Inc (VXRT) is
The price-to-book (P/B) ratio of Vaxart Inc (VXRT) is 1.96
The dividend yield of Vaxart Inc (VXRT) is 0.00%
The market capitalization of Vaxart Inc (VXRT) is $134.37M
The stock symbol (or ticker) of Vaxart Inc is VXRT